Abstract
Background: Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor. Objective: To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers. Methods: A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly). Results: All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73%) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects. Conclusion: Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.
| Original language | English |
|---|---|
| Pages (from-to) | 1095-1099 |
| Number of pages | 5 |
| Journal | International Journal of Dermatology |
| Volume | 46 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2007 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Etanercept for the treatment of refractory pyoderma gangrenosum : A brief series. / Charles, Carlos A.; Leon, Argentina; Banta, Meggan R.; Kirsner, Robert.
In: International Journal of Dermatology, Vol. 46, No. 10, 01.10.2007, p. 1095-1099.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Etanercept for the treatment of refractory pyoderma gangrenosum
T2 - A brief series
AU - Charles, Carlos A.
AU - Leon, Argentina
AU - Banta, Meggan R.
AU - Kirsner, Robert
PY - 2007/10/1
Y1 - 2007/10/1
N2 - Background: Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor. Objective: To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers. Methods: A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly). Results: All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73%) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects. Conclusion: Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.
AB - Background: Pyoderma gangrenosum (PG) is a rare ulcerative inflammatory condition of unknown etiology. Therapy for PG involves local wound care along with topical and systemic anti-inflammatory and other immunodulatory agents. Etanercept is one such immunomodulator with activity against the inflammatory cytokine, tumor necrosis factor. Objective: To evaluate the efficacy and safety of etanercept in the treatment of PG ulcers. Methods: A retrospective analysis was performed on seven patients with 11 refractory PG ulcers treated with subcutaneous injections of etanercept (25-50 mg twice weekly). Results: All seven patients with PG responded well to etanercept. Eight of the 11 ulcers (73%) completely healed with the mean time of (12.5 weeks), while the other three ulcers had marked reduction in size (within 8-18 weeks). Etanercept was well tolerated. No serious side-effects were reported. Only one patient discontinued the drug secondary to side-effects. Conclusion: Etanercept is an alternative treatment option for patients with refractory ulcers due to PG.
UR - http://www.scopus.com/inward/record.url?scp=34848822313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848822313&partnerID=8YFLogxK
U2 - 10.1111/j.1365-4632.2007.03286.x
DO - 10.1111/j.1365-4632.2007.03286.x
M3 - Article
C2 - 17910724
AN - SCOPUS:34848822313
VL - 46
SP - 1095
EP - 1099
JO - International Journal of Dermatology
JF - International Journal of Dermatology
SN - 0011-9059
IS - 10
ER -